121 related articles for article (PubMed ID: 16122187)
1. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M
Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187
[TBL] [Abstract][Full Text] [Related]
2. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride.
Villena-Heinsen C; Friedrich M; Ertan AK; Farnhammer C; Schmidt W
Anticancer Drugs; 1998 Jul; 9(6):557-63. PubMed ID: 9877245
[TBL] [Abstract][Full Text] [Related]
4. Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages.
Villena-Heinsen C; Friedrich M; Ertan AK; Schmidt W
Clin Exp Obstet Gynecol; 1998; 25(1-2):5-8. PubMed ID: 9743868
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
7. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
Burbridge MF; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
Int J Oncol; 1999 Dec; 15(6):1155-62. PubMed ID: 10568822
[TBL] [Abstract][Full Text] [Related]
8. The current and future place of vinorelbine in cancer therapy.
Cvitkovic E; Izzo J
Drugs; 1992; 44 Suppl 4():36-45; discussion 66-9. PubMed ID: 1283849
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo.
Clarke PA; Pestell KE; Di Stefano F; Workman P; Walton MI
Br J Cancer; 2004 Oct; 91(8):1614-23. PubMed ID: 15452549
[TBL] [Abstract][Full Text] [Related]
12. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Aravantinos G; Bafaloukos D; Fountzilas G; Christodoulou C; Papadimitriou C; Pavlidis N; Kalofonos HP; Gogas H; Kosmidis P; Dimopoulos MA
Ann Oncol; 2003 Jul; 14(7):1094-9. PubMed ID: 12853352
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine: a new promising drug in Hodgkin's disease.
Devizzi L; Santoro A; Bonfante V; Viviani S; Bonadonna G
Leuk Lymphoma; 1996 Aug; 22(5-6):409-14. PubMed ID: 8882953
[TBL] [Abstract][Full Text] [Related]
15. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients.
Surowiak P; Materna V; Kłak K; Spaczyński M; Dietel M; Kristiansen G; Lage H; Zabel M
Pol J Pathol; 2005; 56(2):69-74. PubMed ID: 16092668
[TBL] [Abstract][Full Text] [Related]
18. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
19. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts.
Tourell MC; Shokoohmand A; Landgraf M; Holzapfel NP; Poh PS; Loessner D; Momot KI
Sci Rep; 2017 Feb; 7():42905. PubMed ID: 28220831
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
